Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Capricorn payout move could open up NewMed alternative -Palliser

Published 30/11/2022, 13:15
Updated 30/11/2022, 18:15
© Reuters.

By Shadia Nasralla

LONDON (Reuters) -Capricorn Energy's move to ask shareholders for permission to bolster its options for payouts could pave the way for an alternative to its planned merger with NewMed, top-three Capricorn shareholder Palliser told Reuters.

Palliser is one of a chorus of Capricorn investors opposed to a planned merger with NewMed which would create an Israel-Egypt-focused gas producer at a time when Europe is looking for non-Russian gas, but which they say undervalues Capricorn.

Capricorn on Monday called a shareholder meeting for Dec. 15 to get the green light for an accounting move that would give it the option to distribute $495 million, in addition, but separate from, a $620 million special dividend linked to the NewMed deal.

Proxy advisory firm Glass Lewis on Wednesday recommended a vote for the move, according to statement seen by Reuters.

James Smith, chief investment officer at Palliser Capital, told Reuters he believed 40% of Capricorn shareholders shared his opposition to the NewMed deal in its current form.

Palliser has said Capricorn shareholders could get more value than the NewMed deal from Capricorn paying more dividends, cutting costs and optimising its Egyptian assets.

"We believe that Capricorn's announcement ... to increase distributable reserves well beyond the level required for the NewMed transaction could instead facilitate the ... plan we outlined on Oct. 27, thereby catalysing a superior return at meaningfully lower risk for Capricorn shareholders," he said.

In October, Palliser said Capricorn could be valued at 315 pence per share, "a 27% upside to the implied value of the NewMed transaction" and with a potential for further upside in the medium term.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

Capricorn's shares are trading at around 250 pence.

Palliser turned its derivative-based investment into shares this week, becoming Capricorn's third-biggest shareholder with just under a 7% stake, according to Refinitiv data, and with the power to call extraordinary shareholder meetings.

NewMed holds a 45.3% stake in the Leviathan field off the coast of Israel, the largest gas reservoir in the Mediterranean. If the merger goes through, Capricorn shareholders would be left with a 10.3% stake in the combined company.

For Capricorn this marks the second time this year that shareholders have protested against its merger plans. Facing investor opposition, Capricorn terminated plans to merge with Tullow Oil (LON:TLW) and moved on to NewMed instead.

Capricorn declined to comment. NewMed had no immediate comment.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.